Sanofi has removed Chief Executive Officer Paul Hudson after the company’s turnaround efforts failed to deliver the expected pace of progress, triggering a leadership reset at the French vaccine and biopharma major.

The decision comes as Sanofi continues to face pressure on business performance across key segments, particularly within its vaccines and specialty medicines portfolio. The company has been pursuing a strategic transformation aimed at sharpening its innovation focus, strengthening pipeline delivery, and improving commercial execution.

However, slower traction in delivering on these priorities led the board to initiate a leadership change, signalling the need for renewed strategic and operational momentum. The move underscores Sanofi’s intent to realign leadership with its long-term growth roadmap and shareholder expectations.

The transition is expected to influence the company’s near-term business direction, with continued focus on portfolio prioritisation, R&D productivity, and operational performance across global markets.

Like

Dislike

Be a part of Elets Collaborative Initiatives. Join Us for Upcoming Events and explore business opportunities. Like us on Facebook , connect with us on LinkedIn and follow us on Twitter , Instagram.

"Exciting news! Elets technomedia is now on WhatsApp Channels Subscribe today by clicking the link and stay updated with the latest insights!" Click here!